Evidence map›Paper›PMID 35578028›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2022

Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague-Dawley rats fed a high-cholesterol diet.

Rashmi Pathak, Avinash Kumar, Henry A Palfrey, Kirsten P Stone, Narayan R Raju, Thomas W Gettys, Subramanyam N Murthy

Open access · greenAbstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rashmi PathakDepartment of Environmental Toxicology, Southern University and A&M College, 209, Lee Hall, Baton Rouge, LA, 70813, USA.
Avinash KumarDepartment of Environmental Toxicology, Southern University and A&M College, 209, Lee Hall, Baton Rouge, LA, 70813, USA.
Henry A PalfreyDepartment of Environmental Toxicology, Southern University and A&M College, 209, Lee Hall, Baton Rouge, LA, 70813, USA.
Kirsten P StoneNutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, LA, USA.
Narayan R RajuPathology Research Laboratory Inc, South San Francisco, CA, USA.
Thomas W GettysNutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, LA, USA.
Subramanyam N MurthyDepartment of Environmental Toxicology, Southern University and A&M College, 209, Lee Hall, Baton Rouge, LA, 70813, USA. s_murthy@subr.edu.ORCID http://orcid.org/0000-0002-4338-2542
Pennington Biomedical Research Center · USSouthern University and Agricultural and Mechanical College · USLouisiana State University · US

Funding

STABILITY' (symptomatic review during biologic therapy) Review in Inflammatory Bowel DiseaseP20GM103424 · NIGMS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI VLADIMIR N CHOULJENKO · 2012 to 2026
$57.4M
NIGMS NIH HHS P20 GM103424
6 · The paper itself

Abstract

objectiveSitagliptin and other dipeptidyl peptidase (DPP)-4 inhibitors/gliptins are antidiabetic drugs known to improve lipid profile, and confer anti-inflammatory and anti-fibrotic effects, which are independent of their hypoglycemic effects. However, in our previous short-term (35 days) studies, we showed that sitagliptin accentuates the hepato-inflammatory effects of high dietary cholesterol (Cho) in male Sprague-Dawley rats. Since most type 2 diabetics also present with lipid abnormalities and use DPP-4 inhibitors for glucose management, the present study was conducted to assess the impact of sitagliptin during long-term (98 days) feeding of a high Cho diet. An additional component of the present investigation was the inclusion of other gliptins to determine if hepatic steatosis, necro-inflammation, and fibrosis were specific to sitagliptin or are class effects.

methodsAdult male Sprague-Dawley rats were fed control or high Cho (2.0%) diets, and gavaged daily (from day 30 through 98) with vehicle or DPP-4 inhibitors (sitagliptin or alogliptin or saxagliptin). On day 99 after a 4 h fast, rats were euthanized. Blood and liver samples were collected to measure lipids and cytokines, and for histopathological evaluation, determination of hepatic lesions (steatosis, necrosis, inflammation, and fibrosis) using specific staining and immunohistochemical methods.

resultsCompared to controls, the high Cho diet produced a robust increase in NASH like phenotype that included increased expression of hepatic (Tnfa, Il1b, and Mcp1) and circulatory (TNFα and IL-1β) markers of inflammation, steatosis, necrosis, fibrosis, and mononuclear cell infiltration. These mononuclear cells were identified as macrophages and T cells, and their recruitment in the liver was facilitated by marked increases in endothelium-expressed cell adhesion molecules. Importantly, treatment with DPP-4 inhibitors (3 tested) neither alleviated the pathologic responses induced by high Cho diet nor improved lipid profile.

conclusionsThe potential lipid lowering effects of DPP-4 inhibitors were diminished by high Cho (a significant risk factor for inducing liver damage). The robust inflammatory responses induced by high Cho feeding in long-term experiment were not exacerbated by DPP-4 inhibitors and a consistent hepatic inflammatory environment persisted, implying a prospective physiological adaptation.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypercholesterolemiaAnimalsCholesterol, DietaryDietFibrosisHypoglycemic AgentsInflammationMaleNecrosisProspective StudiesRatsRats, Sprague-DawleySitagliptin PhosphateCholesterol, DietaryDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSitagliptin PhosphateDPP-4 inhibitorFibrosisHypercholesterolemiaInflammationNAFLDNecrosis

Identifiers

PMID35578028
PMCPMC10154130
OpenAlexW4280559647

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.